Mobile

Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route)

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-017690-38

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

1) To evaluate the compliance, in terms of immunogenicity, of the influenza vaccine (split virion, inactivated) NH 2010-2011 formulation with the requirements of the Committee for Proprietary Medicinal Products (CPMP) Note for Guidance (NfG) CPMP/BWP/214/96 in both age groups 2) To describe the safety of the influenza vaccine (split virion, inactivated) NH 2010-2011 formulation in both age groups

Critère d'inclusion

  • Vaccination of adults up to 60 years of age an elderly of 61 years of age and over with inactivated split-virion influenza vaccine administerd by intramuscular route

Liens